Cutaneous melanoma is the most common skin cancer with an incidence that has been
rapidly increasing in the past decades. Melanomas are among the most immunogenic …

Cutaneous melanoma arises from the malignant transformation of skin melanocytes; its
incidence and mortality have been increasing steadily over the last 50 years, now …

Simple Summary In this manuscript, we discuss recent updates on melanoma-related
clinical trial data. We explore diverse topics, including new therapeutic agents and novel …

Melanoma is the most aggressive form of skin cancer whose worldwide incidence is rising
faster than any other cancer. Few treatment options are available to patients with metastatic …

Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a
complex etiology. Until 2010, the treatment options for metastatic melanoma were very …

Nowadays, oncogene‐directed therapy and immunotherapy represent the two most
promising avenues for patients with metastatic melanoma. The recent oncogene‐directed …

Abstract The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–
4th, 2015. The four sessions at this meeting were focused on:(1) molecular and immune …

As calculated by the meta-analysis of Korn et al., the prognosis of metastatic melanoma in
the pretarget and immunological therapy era was poor, with a median survival of 6.2 and a 1 …

Historically, the median overall survival for patients with stage IV melanoma was less than 1
year and the 5-year survival rate was∼ 10%. Recent advances in therapy have raised 5 …

Recent advances in treating cutaneous melanoma have resulted in impressive patient
survival gains. Refinement of disease staging and accurate patient risk classification have …